Portal de recerca
ESTUDIO EN FASE 1 ABIERTO, ALEATORIZADO, DE GRUPOS PARALELOS PARA EVALUAR LA FARMACOCINÉTICA, LA EFICACIA Y LA SEGURIDAD DE CT-P13 SUBCUTÁNEO Y CTP13 INTRAVENOSO EN PACIENTES CON ENFERMEDAD ACTIVA DE CROHN Y PACIENTES CON COLITIS ULCEROSA ACTIVA.
Dades bàsiques
- Protocol:
- EURDRACT:
- NCT:
- Centre:
- HOSPITAL DE MANISES
- Any inici:
- 2017
- Any de finalització:
- 2019
Documents
- No hi ha documents
Participants
Resultats de l'Assaig Clínic
Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease
Taxonera, C; (...); SEGURTB study gro GETECCU
Article. 10.1093/ecco-jcc/jjx022. 2017
Effect of the HLA-DQA1*05 allele on the efficacy of ustekinumab in patients with Crohn's Disease. Multicenter study based on the ENEIDA registry of GETECCU.
Guardiola Capon, J.; (...); Rodriguez-Moranta, F.
Meeting Abstract. 2024
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.
Casanova MJ; (...); Gisbert JP
Article. 10.1093/ibd/izz192. 2020
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease
Chaparro, M; (...); Gisbert, JP
Meeting Abstract. 2019
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease.
Chaparro M; (...); Gisbert JP
Article. 10.1177/1756284819867848. 2019
Granulocyte-monocyte apheresis combination therapy after loss of response to anti-TNF drugs
Rodriguez-Lago, I; (...); Cabriada, JL
Meeting Abstract. 2018
Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA
Gargallo-Puyuelo, C.; (...); Gomollon, F.
Meeting Abstract. 2023
Neuropsychological assessment and cortisol levels in biofluids from early Alzheimer's disease patients
Pena-Bautista, C.; (...); Chafer-Pericas, C.
Article. 10.1016/j.exger.2019.05.007. 2019
Plasma lipid peroxidation biomarkers for early and non-invasive Alzheimer Disease detection
Pena-Bautista, C; (...); Chafer-Pericas, C
Article. 10.1016/j.freeradbiomed.2018.06.038. 2018
Primary prevention of post-operative recurrence of Crohn's disease with anti-TNF agents in real life. Preliminary data from the Spanish ENEIDA registry
Canete, F; (...); Domenech, E
Meeting Abstract. 2018
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial
Taxonera, C; (...); Nos, P
Article. 10.1016/j.dld.2019.01.002. 2019
Real-world long-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA registry
Iborra Colomino, M. I.; (...); Nos, P.
Meeting Abstract. 2020
Recommendations of the Crohn's Disease and Ulcerative Colitis Spanish Working Group (GETECCU) for the treatment of perianal fistulas of Crohn's disease.
Boscá MM; (...); Hinojosa J
Review. 10.1016/j.gastrohep.2019.09.012. 2020
Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry
Calafat, M; (...); Domenech, E
Meeting Abstract. 10.1093/ecco-jcc/jjy222.561. 2019
Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease
Taxonera, C; (...); CONVERT Study Grp GETECCU
Article. 10.1093/ecco-jcc/jjy104. 2018
The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn's disease but not in ulcerative colitis. A nationwide study from the Eneida registry
Guasch, M; (...); Domenech, E
Meeting Abstract. 2018
The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case-control study of the ENEIDA registry
Calafat, M; (...); Domenech, E
Meeting Abstract. 2018
Vedolizumab, an adequate option in medically refractory and thiopurine-intolerant inflammatory bowel disease patients
Meeting Abstract. 2018
Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents
Article. 10.1016/j.gastrohep.2018.06.001. 2018